LYMEPOLICYWONK: Lyme Patients and Insurance Appeals

I looked into this in depth in California and wrote many, many, (too many) letters to the California Department of Managed Health Care.  Then I called them and tried to talk with human beings and reason with them.  I said, “look, Lyme patients are being systematically discriminated against–you have a systemic bias in your system that causes us to lose these appeals.  Tell me what can we do.  Can I educate the reviewers that there are two standards of care?”  The answer, ultimately, after many, many, (too many) conversations was that the reviews were sent to “independent review organizations” (IROs).  IROs spend their days doing claims appeal work for insurance companies and their nighttimes reviewing appeals by patients.  How do you think the process goes?  Well, they reach into their IDSA guidelines folder, which they used during the day, and pull out the IDSA guidelines and apply them.  It does not matter that there are two standards of care to IROs.  They’re just doing their job.  And, if you want to educate these folks regarding two standards of care.  Forget it.  As far as the CDMHC cares, your appeal goes into a black box that cannot be educated, advised, informed, or intervened with.

So what do I tell patients to do?  I tell them to file the appeals.  Let’s get the stats.  When I gave my presentation before the IDSA review panel, I told them about the disparity.  I had the stats.  The chair asked “is that just California”–as though California was not a state that mattered much in the scheme of things.  I said, “it is just California that I looked at, but I would be surprised it this varies state to state. Independent Review Organizations operate nationwide.”

Here is the challenge.  Find out where you file appeals for an independent review in your state when insurance denies a claim. (Almost all states have this process.)  Find out if they have a data base.  See if you can search for all cases appealed and how many succeeded. Then do a search for how many Lyme case appeals were filed and how many succeeded.  Report back.  I want to know.  Send me you results to my email address below.

 

You can contact Lorraine Johnson, JD, MBA at lbjohnson@lymedisease.org.

Similar Posts

  • Medical antitrust actions–Does “might make right”?

    Antitrust law is concerned with constraints of trade that foreclose consumer choice. Guidelines developed by medical specialty societies that have monopoly power (like the IDSA) can become de facto legal standards for the practice of medicine. When they foreclose treatment options and the exercise of clinical judgment, they constrain consumer choice.

    Typically, laws are passed in the United States through a democratic process that allows many groups to have a voice in the law before it is passed. Antitrust laws make an exception to guidelines or standards that are developed by groups that have expertise in an area (for instance, computer chips and medicine) so long as they play fair. The reason for this exception is that the level of expertise required in these areas makes it reasonable for "experts" rather than laymen to be setting the rules.

  • LYMEPOLICYWONK: IOM Hearings—Same Old, Same Old?

    Labor HHS 2010 appropriations language directed the National Institutes of Health (NIH) to“sponsor a scientific conference on Lyme and tick-borne diseases” and mandated that the conference represent the broad spectrum of scientific views…and provide a forum for public participation and input from individuals with Lyme disease.” Rather than conducting this review themselves as an NIH State of the Science conference as anticipated, the NIH subcontracted the work out to the Institute of Medicine. Looked at in the most kindly light, perhaps they regarded the Lyme controversy as “too hot to handle” or “not in my backyard”. A less charitable viewpoint would characterize the shunt to the IOM as “forum shopping”—a way of selecting a process that is most likely to favor a desired outcome.

  • LYMEPOLICYWONK: MUS is DUMB—Doctors with Unexplained Medical Beliefs

    You’ve all heard that the latest drum-roll from the rheumatologists at the IDSA hearing was essentially to say that Lyme patients have persistent symptoms and they started off with infection, but now we don’t “believe” in persistence—so what do you call it? How about “medically unexplained symptoms” or MUS for short? All of this seems to regard the real problem with Lyme disease as being what you call it. But patients know the real problem with Lyme disease is how you treat it, how you cure it, how you restore patients to their lives. Disease definitions like MUS are for drug-makers who sell drugs to a market, physicians trying to claim professional turf, and insurers trying to deny treatment reimbursement. They are not for patients. Abraham Lincoln had it right when he said: “How many legs does a dog have if you call the tail a leg? (Answer) Four. Calling a tail a leg doesn't make it a leg.” I’m not the only one who finds these acronyms aggravating and unhelpful. A post from the internet nails it:

  • At the Gala

    Every now and then you gotta kick up your heels. This year I headed back east for Time for Lyme's GALA. The Young People's Chorus of New York City gave an amazing performance of internationally inspired songs. Actor, Director and Writer Lou Diamond Phillips of Lyme Life gave a compelling speech and a rousing performance singing with the band–including the song LA BAMBA–which had everyone up dancing. The picture is me leaning in to talk with Dr. Luc Montagnier, a Nobel Prize winner for his discovery of HIV, who was honored at the GALA.

  • When is a public hearing not public—the sequel?

    The IDSA settlement agreement calls for an open public meeting which must be aired live over the internet. I have serious concerns about the restrictions the IDSA is imposing on people who want to watch the hearings and am discussing these with the Connecticut Attorney General’s office, but meanwhile I want to provide you with information so that if you want to watch you are prepared.